Appraisal of bone targeting potential of nanohydroxyapatite based drug carriers conjugated with pamidronate in osteoporosis treatment.
Several past studies have showed that mPEG-PLGA offer numerous prospects for the design of controlled release systems. For that reasons, nanoparticles prepared by PLGA and mPEG are used as a carrier to achieve a sustained drug release. We modified the surfaces of the nanoparticles with Pamidronate and mPEG hydrophilic components to evaluate the potency of their targeted delivery to bone for the treatment of Osteoporosis. The present investigation aims to evaluate the target potential of mPEG-PLGA-PAM-HA nanoparticle to the bone tissue. Pamidronate (PAM) was conjugated to PLGA by carbodiimide chemistry. Mono-methoxy polyethylene- Polylactide-co-glycolide (mPEG-PLGA) block polymers were synthesized by ring-opening polymerization and used to avoid its uptake by RES. Pamidronate (PAM) was adsorbed on the surface of hydroxyapatite (PAM-HA) and it was conjugated with various ratios of mPEG-PLGA. The formation of surface-modified mPEG-PLGA nanoparticle prepared with different ratios of Pamidronate and hydroxyapatite was confirmed by 1H NMR and FT-IR. The average particle size, zeta potential and % EE were found to be 96.7 ± 2.3 nm, -30 ± 1.2 mV and 89.0 ± 1.0 % respectively. SEM and TEM analysis revealed spherical morphology and uniformity of nanoparticles. In pharmacodynamic studies such as histopathology and volumetric bone density (VBD) of bones, it has been observed that mPEG-PLGA-PAM-HA nanoparticles enhance the bone micro-architecture in rat model when compared with other groups. The result shows that the mPEG-PLGA-PAM-HA NPs can play a pivotal role in osteoporosis treatment when compare with the single dose of marketed formulation.